Ranibizumab

Susvimo (PDS with ranibizumab) is approved by FDA treatment for neovascular or “wet” age-related macular degeneration (nAMD)

Basel, 22 October 2021 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD) who have previously responded to…